Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamotrigine for Treatment of Myotonia
2013-003309-24Phase 3Terminated
- Sponsor
- Grete Andersen
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of lamotrigine in myotonia, myotonic dystrophy type 1 (DM1), myotonic dystrophy type 2 (DM2) and 4 more, sponsored by Grete Andersen. Primary endpoint: Patient-reported muscle stiffness (MBS). Started Oct 2013; status: terminated.
02
Drugs
lamotrigine
03
Conditions
myotoniamyotonic dystrophy type 1 (DM1)myotonic dystrophy type 2 (DM2)myotonia congenita (MC)paramyotonia congenita (PMC)
Beyond the preview
Go deeper on 2013-003309-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003309-24.